CORMEDIX INC

NASDAQ: CRMD (CorMedix Inc.)

最近更新时间: 20小时之前

4.82

0.16 (3.43%)

前收盘价格 4.66
成交量 3,195,451
预期市盈率 (P/E Forward) 33.21
价格/销量 (P/S) 1.07
股市价格/股市净资产 (P/B) 0.800
52周波幅
4.65 (-3%) — 13.02 (170%)
营业毛利率 20.81%
营业利益率 (TTM) 51.49%
稀释每股收益 (EPS TTM) 0.250
总债务/股东权益 (D/E MRQ) 0.41%
流动比率 (MRQ) 4.21
营业现金流 (OCF TTM) -13.57 M
杠杆自由现金流 (LFCF TTM) -21.07 M
资产报酬率 (ROA TTM) 8.31%
股东权益报酬率 (ROE TTM) 19.87%

AIStockmoo 评分

-0.1
价值 30% 0.7
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
负债低。盈利能力强。短期流动性充足。现金流为负。 参考
资本回报低于资本成本。资本回报上升。 参考
时机 30% -3.4
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年呈下降趋势。股价远低于52周高点。 参考
近期出现看涨反转形态:倒锤子线。 参考
您持有期的趋势 参考 NA
市场情绪 20% 0.3
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻好坏参半或中性。 参考
聪明钱 20% 3.5
内部交易活动 参考 NA
机构在最新13F申报中净+5.68%的股份:99家增持,90家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-11.4%,回补天数8.4天(FINRA)。 参考
市场和行业状况不佳。
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向不一,评分因此减弱。
不计入评分
股价低于其52周平均水平。 参考
短、中、长期趋势均向下。短期动能下降。 参考
支撑与阻力没有明确信号。 参考
最终评分 -0.06

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 CorMedix Inc. 混合的 看跌

相关股票

股票 市值 DY P/E(TTM) P/B
CRMD - - - 0.800
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
MLTX - - - 2.79
VKTX - - - 6.33
VSTM - - - 76.50

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 1.08%
机构持股比例 34.20%

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 64.78%

持仓变动 机构数 股数
增持 99 7,583,312
减持 90 3,469,708
新建仓 31 1,461,982
清仓 20 1,030,741

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 14,205,973 8.4
15 Oct 2026 14,665,697 12.7
30 Sep 2026 15,422,728 18.9
15 Sep 2026 16,202,272 18.5
31 Aug 2026 16,032,112 13.0
14 Aug 2026 17,149,908 11.1

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

7 正面 3 负面 4 中性
日期 类型 细节
13 Nov 2026 Yahoo Finance CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
CorMedix's (CRMD) DefenCath and Rezzayo medications are expected to drive 2027 growth, in addition t…
13 Nov 2026 Yahoo Finance CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
12 Nov 2026 Yahoo Finance CorMedix Inc. Q3 2026 Earnings Call Summary
Moby summary of CorMedix Inc.'s Q3 2026 earnings call…
12 Nov 2026 Yahoo Finance CorMedix (CRMD) Q3 2026 Earnings Call Transcript
Heron deal and DefenCath reimbursement shifts drive the quarter.
12 Nov 2026 Yahoo Finance What CorMedix (CRMD) Said on Its Q3 Earnings Call
CorMedix (NASDAQ:CRMD) reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics’ assets and deferred 2027 guidance for the dialysis treatment. Revenue fell to $54.5 million fr…
12 Nov 2026 Yahoo Finance CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +55.56% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
12 Nov 2026 Yahoo Finance CorMedix: Q3 Earnings Snapshot
(CRMD) on Thursday reported a loss of $14.On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 19 cents.
12 Nov 2026 Yahoo Finance Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for…
10 Nov 2026 Yahoo Finance CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
10 Nov 2026 Yahoo Finance CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
CorMedix (NASDAQ:CRMD) has agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial products and a development agreement to its portfolio of medicines used in hospitals and other institutional settings. CorMedix will pay $145 million in cash and approximately 14.6 m…
09 Nov 2026 Yahoo Finance CorMedix stock gains as Heron deal adds four products
Investing.com -- CorMedix Inc (NASDAQ:CRMD) shares rose 4.5% in premarket trading Monday after the company announced it will acquire substantially all assets of Heron Therapeutics Inc (NASDAQ:HRTX) for approximately $222.6 million. Heron stock surged 45% on the news.
09 Nov 2026 Yahoo Finance CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common…
06 Nov 2026 Yahoo Finance CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call…
04 Nov 2026 Yahoo Finance Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02 Nov 2026 Yahoo Finance CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position
CorMedix Therapeutics (NASDAQ:CRMD) has maintained its full-year 2026 revenue guidance of $325 million to $345 million and reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, according to a business update released on November 2. The pharmaceutical…
02 Nov 2026 Yahoo Finance CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance. Business Updates CorMedix announces…
显示更多

近期信号 K线形态与EMA交叉

▲ 倒锤子线 2个交易日前 · 12 Nov
下跌后出现小实体和长上影线:买方在试探上方。需要下一交易日收高确认。

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票